S
Samuel R. Larson
Researcher at Baylor College of Medicine
Publications - 5
Citations - 19
Samuel R. Larson is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Hepatoblastoma & Internal medicine. The author has an hindex of 2, co-authored 2 publications receiving 7 citations. Previous affiliations of Samuel R. Larson include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma.
Sarah E. Woodfield,Yan Shi,Roma H. Patel,Zhenghu Chen,Aayushi P. Shah,Rohit Kumar Srivastava,Richard S. Whitlock,Aryana M. Ibarra,Samuel R. Larson,Stephen F. Sarabia,Andrew Badachhape,Zbigniew Starosolski,Ketan B. Ghaghada,Pavel Sumazin,D. Allen Annis,Dolores Lopez-Terrada,Sanjeev A. Vasudevan +16 more
TL;DR: In this article, the p53 regulator Murine double minute 4 (MDM4) was used to reactivate p53 signaling in a murine model of Hepatoblastoma (HB) patients.
Journal ArticleDOI
Cardiac dysregulation following intrahippocampal kainate-induced status epilepticus.
Amber T. Levine,Heather A. Born,Andrew P. Landstrom,Samuel R. Larson,Samuel R. Larson,Wai Ling Lee,Wai Ling Lee,An T. Dao,An T. Dao,Xander H.T. Wehrens,Yi-Chen Lai,Yi-Chen Lai,Anne E. Anderson +12 more
TL;DR: Heart rhythm abnormalities were more frequent during the light cycle and were not correlated with increased epileptiform activity or seizure frequency, and SE animals had early mortality, and a death event captured during vEEG recording demonstrated severe bradycardia prior to death.
Journal ArticleDOI
Abstract 1825: Romidepsin therapy results in p53 mediated apoptosis in hepatoblastoma
Andres F. Espinoza,Richard P. Whitlock,Rohit Srivastava,Roma H. Patel,Saiabhiroop R. Govindu,Aayushi P. Shah,Samuel R. Larson,Sarah E. Woodfield,Sanjeev A. Vasudevan +8 more
TL;DR: Romidepsin demonstrates strong in vitro efficacy and suggest HDAC 2/3 inhibition may act through p53 mediated mechanism, notably acetylated p53, and suggest cell death via apoptosis is further supported by cell death reversal with ZVAD/RomidePSin treatment in HB cell lines.
Journal ArticleDOI
Abstract PO013: Patient-derived xenograft mouse models of hepatoblastoma for a personalized medicine pipeline
Sarah E. Woodfield,Roma H. Patel,Andres F. Espinoza,Richard P. Whitlock,Jessica Epps,Andrew Badachhape,Samuel R. Larson,Rohit Srivastava,Aayushi P. Shah,Saiabhiroop R. Govindu,Barry Zorman,Brandon Mistretta,Kevin E. Fisher,Ilavarasi Gandhi,Jacquelyn Reuther,M.J. Urbicain,Aryana M. Ibarra,Sakuni Rankothgedera,Kimberly R. Holloway,Stephen F. Sarabia,Andras Heczey,Ketan B. Ghaghada,Kalyani R. Patel,Dolores Lopez-Terrada,Angshumoy Roy,Preethi H. Gunaratne,Pavel Sumazin,Sanjeev A. Vasudevan +27 more
TL;DR: These novel orthotopic PDX models of HB fully recapitulate the primary tumors and represent a platform for clinically relevant drug screening and testing and indicate a spectrum of sensitivity to cisplatin, a frontline standard chemotherapy agent.
Journal ArticleDOI
Abstract 3891: Efficacy of dinaciclib in hepatoblastoma through inhibition of cyclin dependent kinases
Rohit Srivastava,Roma H. Patel,Andres F. Espinoza,Yang Yu,Richard P. Whitlock,Samuel R. Larson,Andrew Badachhape,Jianhua Yang,Sarah E. Woodfield,Sanjeev A. Vasudevan +9 more
TL;DR: Dinaciclib treatment showed promising effects with preclinical HB cell lines and PDX models and in vivo models, and suppressed cell proliferation and viability in a dose-dependent manner.